GPN Vaccines
Biotechnology ResearchView the employees at
GPN Vaccines-
Erin Brazel Postdoctoral Research Scientist | Research Centre for Infectious Diseases
-
Australia
-
Rising Star
Jacqueline Morey Senior Research Scientist | Advocate for improved ECR support & wellbeing | DEI in STEM-
Rising Star
Manon Cox Chief Executive Officer & Co-Founder at NextWaveBio-
East Haven, Connecticut, United States
-
Top 5%
Malachi Obst Research Assistant | GPN Vaccines-
Greater Adelaide Area
-
Rising Star
Eve Kennedy Director of Research Operations at GPN Vaccines-
Adelaide, South Australia, Australia
-
Rising Star
Overview
GPN Vaccines is developing a broad-spectrum vaccine against Streptococcus pneumoniae, which causes life-threatening pneumonia, meningitis, and sepsis, as well as otitis media in children. Up to two million deaths worldwide are attributed to S. pneumoniae each year, killing more children than AIDS, malaria and tuberculosis combined. The best vaccine available only protects against 20 of the 100 known strains. GPN Vaccines is therefore developing a novel, whole-cell vaccine to provide adults and children with broad-spectrum protection against S. pneumoniae, regardless of the strain.
-